<code id='79D33EC96D'></code><style id='79D33EC96D'></style>
    • <acronym id='79D33EC96D'></acronym>
      <center id='79D33EC96D'><center id='79D33EC96D'><tfoot id='79D33EC96D'></tfoot></center><abbr id='79D33EC96D'><dir id='79D33EC96D'><tfoot id='79D33EC96D'></tfoot><noframes id='79D33EC96D'>

    • <optgroup id='79D33EC96D'><strike id='79D33EC96D'><sup id='79D33EC96D'></sup></strike><code id='79D33EC96D'></code></optgroup>
        1. <b id='79D33EC96D'><label id='79D33EC96D'><select id='79D33EC96D'><dt id='79D33EC96D'><span id='79D33EC96D'></span></dt></select></label></b><u id='79D33EC96D'></u>
          <i id='79D33EC96D'><strike id='79D33EC96D'><tt id='79D33EC96D'><pre id='79D33EC96D'></pre></tt></strike></i>

          knowledge

          knowledge

          author:Wikipedia    Page View:82913
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more
          After sickle
          After sickle

          MollyFerguson/STATTheapprovalFridayofBluebirdBio’sgenetherapyforsicklecelldiseaseshouldhavebeenamome

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Roche to buy Carmot Therapeutics, developer of obesity drugs

          SebastienBozon/AFPviaGettyImagesLONDON—Theboomingobesitymarketisattractinganotherplayer,aspharmagian